Appointment booking for Dr. Shailender Karry Mohanrao, MD is currently not available.Dr. Shailender Karry Mohanrao, MD has not yet fully activated their profile on DiabetesIQ.
Dr. Shailender Karry Mohanrao, MD (he/him) is a Internist in Maplewood, NJ with over 18 years of experience. What is your opinion of Dr. Shailender Karry Mohanrao, MD? Rate this provider below so other people can make informed decision.
Gender
Male
Experience
Over 18 Years of Experience
Languages Spoken
English
Accepted Insurances
Medicare
Payments Received
Many providers receive payments from medical companies such as pharmaceutical companies and medical device companies. These payments can range from small amounts for meals to large consulting fees. We provide this information in order to make healthcare system more transparent. Between 2014 and 2020 Dr. Shailender Karry Mohanrao, MD has received over $1,491 which includes payments from the following companies:
$305.41 from Merck Sharp & Dohme Corporation
$242.69 from Boehringer Ingelheim Pharmaceuticals, Inc.
$221.88 from Takeda Pharmaceuticals America, Inc.
$195.89 from Astellas Pharma US Inc
$114.24 from Avanir Pharmaceuticals, Inc.
$100.00 from Purdue Pharma L.P.
$75.43 from Amarin Pharma Inc.
$58.24 from Medtronic Vascular, Inc.
$32.67 from Amgen Inc.
$27.50 from Janssen Pharmaceuticals, Inc
$25.40 from Novo Nordisk Inc
$23.18 from AstraZeneca Pharmaceuticals LP
$22.71 from Avion Pharmaceuticals
$18.60 from LILLY USA, LLC
$14.97 from Arbor Pharmaceuticals, Inc.
$12.50 from E.R. Squibb & Sons, L.L.C.
Payments received by Dr. Shailender Karry Mohanrao, MD were from the following categories:
Do you have any questions about your diabetes condition or general questions about diabetes? You can now post those questions in DiabetesIQ Forum and have our diabetes experts answer your questions for FREE! Yes, there is absolutely no catch! - Registration only takes a few seconds and it's FREE. No credit card needed. You can ask any number of diabetes questions, all for FREE! Register today and join the conversation!